These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8993504)

  • 1. Induction of apoptosis by camptothecin and topotecan.
    Traganos F; Seiter K; Feldman E; Halicka HD; Darzynkiewicz Z
    Ann N Y Acad Sci; 1996 Dec; 803():101-10. PubMed ID: 8993504
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction of apoptosis by topotecan: implications for the treatment of leukemia.
    Seiter K
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):22-5. PubMed ID: 9779878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of camptothecin treatment on topoisomerase II alpha expression in ML-1 and HL-60 leukemia cell lines.
    Nair J; Traganos F; Tse-Dinh YC
    Anticancer Res; 2000; 20(6B):4183-8. PubMed ID: 11205246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cell cycle effects of camptothecin.
    Darzynkiewicz Z; Bruno S; Del Bino G; Traganos F
    Ann N Y Acad Sci; 1996 Dec; 803():93-100. PubMed ID: 8993503
    [No Abstract]   [Full Text] [Related]  

  • 5. Relation between intracellular acidification and camptothecin-induced apoptosis in leukemia cells.
    Goossens JF; Hénichart JP; Dassonneville L; Facompré M; Bailly C
    Eur J Pharm Sci; 2000 Apr; 10(2):125-31. PubMed ID: 10727878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase I-targeting drugs as radiation sensitizers.
    Chen AY; Choy H; Rothenberg ML
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical studies of camptothecin and derivatives.
    Soepenberg O; Sparreboom A; Verweij J
    Alkaloids Chem Biol; 2003; 60():1-50. PubMed ID: 14593855
    [No Abstract]   [Full Text] [Related]  

  • 8. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
    McDonald AC; Brown R
    Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity.
    Morris EJ; Geller HM
    J Cell Biol; 1996 Aug; 134(3):757-70. PubMed ID: 8707853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
    Cohen DP; Adams DJ; Flowers JL; Wall ME; Wani MC; Manikumar G; Colvin OM; Silber R
    Leuk Res; 1999 Nov; 23(11):1061-70. PubMed ID: 10576512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
    Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
    Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-proliferative and apoptosis-inducing effects of camptothecin-20(s)-O-(2-pyrazolyl-1)acetic ester in human breast tumor MCF-7 cells.
    Chu C; Xu J; Cheng D; Li X; Tong S; Yan J; Li Q
    Molecules; 2014 Apr; 19(4):4941-55. PubMed ID: 24747650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Camptothecin causes cell cycle perturbations within T-lymphoblastoid cells followed by dose dependent induction of apoptosis.
    Johnson N; Ng TT; Parkin JM
    Leuk Res; 1997 Oct; 21(10):961-72. PubMed ID: 9403007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase I inhibitors: topotecan and irinotecan.
    Jones SF; Burris HA
    Cancer Pract; 1996; 4(1):51-3. PubMed ID: 8788772
    [No Abstract]   [Full Text] [Related]  

  • 16. Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic.
    Besterman JM
    Ann N Y Acad Sci; 1996 Dec; 803():202-9. PubMed ID: 8993513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of hydroxycamptothecin and topotecan to SKOV3 and CAOV3 in vitro].
    Sun Z; Shen K; Xu X
    Zhonghua Fu Chan Ke Za Zhi; 1999 Sep; 34(9):547-50. PubMed ID: 11360641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent clinical advances with camptothecin analogues.
    Slichenmyer WJ; Donehower RC
    Cancer Treat Res; 1995; 78():29-43. PubMed ID: 8595145
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs.
    Voeller DM; Grem JL; Pommier Y; Paull K; Allegra CJ
    Cancer Chemother Pharmacol; 2000; 45(5):409-16. PubMed ID: 10803925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.